Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy

ConditionMyoma;Uterus

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexFemale

Age25-48

SponsorCairo University

About this trial

The goal of this randomized clinical trial is to determine whether intramyometrial ergometrine injection or intramyometrial carbetocin injection is more effective in reducing blood loss during and after abdominal myomectomy in women undergoing surgery for symptomatic uterine fibroids.

The main questions it aims to answer are:

Does intramyometrial ergometrine reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Does intramyometrial carbetocin reduce intraoperative and postoperative blood loss during abdominal myomectomy?

Is there a difference between the two drugs in the need for blood transfusion and postoperative hemoglobin drop?

Researchers will compare intramyometrial ergometrine injection with intramyometrial carbetocin injection to see which intervention is more effective in controlling surgical bleeding and improving surgical outcomes.

Participants will:

Undergo abdominal myomectomy for uterine fibroids

Receive either intramyometrial ergometrine or intramyometrial carbetocin during surgery

Be monitored for intraoperative blood loss, postoperative blood loss, hemoglobin changes, and need for blood transfusion

Eligibility criteria

Qualifiers

Female participants aged 25 to 48 years

Body mass index (BMI) < 35 kg/m²

Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms)

Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagnosed by transvaginal ultrasonography or magnetic resonance imaging

Disqualifiers

FIGO type 0, 1, 2, 7, or 8 myomas (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal)

History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection

History of prior uterine surgery

Use of hormonal treatment within 3 months prior to enrollment

Trial design

Treatments tested in this trial

Methylergometrine (Intramyometrial Injection)
Carbetocin (Intramyometrial Injection)

Treatment groups

40 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Cairo University

Lead sponsor

Kafrelsheikh University

Sponsor institution

Kafrelsheikh University

Collaborator

Source ClinicalTrials.gov